Every Form 4 that Twist Bioscience Corporation (TWST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TWST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TWST filings page.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a combination of option exercise and share sales in common stock. She exercised employee stock options to acquire 16,470 shares at an exercise price of $8.82 per share, then sold 16,470 shares in multiple open‑market transactions at prices ranging from $65.3256 to $68.6141 per share. After these transactions, she directly owns 861,860 shares of Twist common stock. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on May 27, 2025.
Twist Bioscience Corp director Melissa A. Starovasnik sold 2,500 shares of Common Stock in an open-market transaction at $68.00 per share. The trade took place on May 28, 2026 and was reported as a direct ownership transaction.
Following this sale, she directly holds 22,222 shares of Twist Bioscience Corp. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the sale was scheduled in advance.
Twist Bioscience Corp director Melissa A. Starovasnik sold 500 shares of Common Stock in an open-market transaction. The sale occurred on May 26, 2026 at a price of $61.04 per share. After this transaction, she continues to hold 24,722 shares directly. The company notes that this trade was carried out under a previously adopted Rule 10b5-1 trading plan, indicating it was pre-scheduled rather than a discretionary market-timing decision.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an exercise-and-sell transaction under a pre-arranged Rule 10b5-1 trading plan. She exercised options to acquire a total of 49,299 shares of common stock at an exercise price of $8.82 per share and sold the same number of shares in open-market transactions.
The sales covered 24,282 shares at a weighted average price of $65.0789 per share, 23,752 shares at $65.2392 per share, and 1,265 shares at $66.2813 per share. After these transactions, she continues to hold 846,872 shares of Twist Bioscience common stock directly, along with remaining employee stock options, including awards exercisable into 64,950 shares at an exercise price of $67.85 per share.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported a small mandated stock sale to cover taxes. On the transaction date, he sold 800 shares of common stock in an open-market transaction at an average price of $62.484 per share.
According to the footnote, this sale was required to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After this sale, Werner directly holds 48,186 shares of Twist Bioscience common stock.
Twist Bioscience Corp SVP of Human Resources Paula Green reported an open-market sale of 1,399 shares of common stock at $53.257 per share. According to the footnote, this transaction was a mandated “sell to cover” to satisfy tax withholding obligations tied to vesting Restricted Stock Units, rather than a discretionary trade. After the sale, she directly holds 121,589 shares of Twist Bioscience common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported a mandated sale of 4,160 shares of common stock. The shares were sold on May 21, 2026 at an average price of $53.257 per share to cover tax withholding obligations from vesting Restricted Stock Units.
According to the disclosure, this was a required "sell to cover" transaction under the company’s equity incentive plans and did not represent a discretionary trade by Finn. After the sale, he directly held 274,804 shares of Twist Bioscience common stock.
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 1,642 shares of Common Stock at $53.257 per share. According to the filing, these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, pursuant to a mandated “sell to cover” election rather than a discretionary trade. After this transaction, Cho directly holds 134,299 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported an insider stock sale tied to tax withholding. On May 21, 2026, he sold 688 shares of common stock at $53.257 per share in an open-market transaction.
According to the footnote, the shares were sold solely to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity incentive plans, and did not represent discretionary trading. After this mandated “sell to cover” transaction, Werner directly holds 48,986 common shares of Twist Bioscience.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a mandated sale of 6,888 shares of Common Stock on May 21, 2026 at an average price of $53.257 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, and the transaction did not represent a discretionary trade by the CEO. Following this transaction, Leproust directly held 846,872 shares of Twist Bioscience Common Stock and retained employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share, expiring on August 31, 2030.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,019 shares of common stock at an average price of $53.257 per share. According to the footnote, these shares were sold solely to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans and were not discretionary trades. After this transaction, Laponis directly holds 116,675 shares of Twist Bioscience common stock.
Twist Bioscience Corp director Jan Johannessen reported an option exercise and related share sale. Johannessen exercised employee stock options for 12,000 shares of common stock at $14.00 per share, increasing his holdings to 29,754 shares. On the same day, he completed an open-market sale of 12,000 common shares at an average price of $56.12 per share, leaving him with 17,754 shares held directly after the transactions. The options exercised had vested in stages over several years, subject to his continuous service.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported an open-market sale of Common Stock. He sold 4,961 shares on May 8, 2026 at a price of $56.881 per share. After this transaction, he directly holds 49,674 shares of Twist Bioscience Common Stock.
Twist Bioscience Corp officer Dennis Cho reported a small mandated share sale linked to tax withholding. On May 4, 2026, he sold 1,962 shares of common stock at $57.1488 per share to cover taxes due on vesting Restricted Stock Units. After this transaction, he directly holds 135,941 shares of Twist Bioscience common stock, and the filing notes these sales were required under the company’s equity incentive plan and were not discretionary trades.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 5,127 shares of Common Stock at an average price of $57.1488 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans and are described as non-discretionary "sell to cover" transactions.
Following this tax-related sale, Leproust directly holds 853,760 shares of Common Stock. She also holds an employee stock option that is exercisable for 64,950 shares of Common Stock at an exercise price of $67.8500 per share, with an expiration date of August 31, 2030.
Twist Bioscience Corp SVP Paula Green reported an open-market sale of 1,116 shares of common stock at $57.1488 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After the transaction, she directly holds 122,988 shares of Twist Bioscience common stock.
Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 2,844 shares of common stock at an average price of $57.1488 per share. The footnote explains these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
The filing states these “sell to cover” transactions are mandated by the issuer’s plan election and are not discretionary trades by the executive. After this tax-related sale, Finn directly holds 278,964 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer Robert F. Werner reported a small, mandated share sale tied to equity compensation taxes. On May 4, 2026, he sold 164 shares of common stock at $57.1488 per share to cover tax withholding from vesting Restricted Stock Units.
The company’s equity incentive plan requires these “sell-to-cover” transactions, and the footnote states they are not discretionary trades by Werner. After this tax-related sale, he directly owns 54,635 shares of Twist Bioscience common stock.
Twist Bioscience Corp director Melissa A. Starovasnik sold shares in a planned transaction. On April 27, 2026, she completed an open-market sale of 500 shares of Common Stock at $61.83 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating it was scheduled in advance. After this transaction, she continues to hold 25,222 shares directly.
Twist Bioscience Corp’s President and COO Patrick John Finn reported an open-market sale of 2,321 shares of Common Stock at $60.761 per share. According to the footnote, these shares were sold solely to cover tax withholding triggered by vesting of Restricted Stock Units under the company’s equity plans and were not discretionary trades. After this transaction, he directly holds 281,808 shares of Twist Bioscience common stock.
Twist Bioscience CEO Emily M. Leproust reported option-related trades in Common Stock. She exercised employee stock options to acquire 9,671 shares at an exercise price of $8.82 per share, then sold 9,671 shares in open‑market transactions at prices around $65–66 per share under a pre‑arranged Rule 10b5‑1 trading plan. After these transactions she directly owns 858,887 shares of Common Stock and retains employee stock options, including a grant tied to 64,950 underlying shares with a $67.85 exercise price.
Twist Bioscience Corp Chief Financial Officer Adam Laponis sold 4,000 shares of Common Stock in an open-market transaction. The sale occurred at a price of $60.00 per share on April 17, 2026. After this transaction, he directly holds 118,694 shares of Twist Bioscience common stock.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that Laponis previously adopted on May 8, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.
Twist Bioscience Corp’s Chief Financial Officer, Adam Laponis, reported an open-market sale of 3,000 shares of common stock at $55.00 per share. The transaction was made under a previously adopted Rule 10b5-1 trading plan. Following this sale, he continues to hold 122,694 shares directly.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,597 shares of common stock on April 9, 2026 at an average price of $49.889 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans, and were not discretionary trades. After this transaction, Laponis directly holds 125,694 shares of Twist Bioscience common stock.
Twist Bioscience director Melissa A. Starovasnik executed an open-market sale of 1,000 shares of Common Stock at $51.00 per share on April 1, 2026. After the transaction, she directly holds 25,722 shares of Twist Bioscience common stock.
The filing notes that this sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 22, 2025, indicating the transaction was planned in advance rather than timed discretionarily.
Twist Bioscience Corp officer Dennis Cho reported a mandated sale of 354 shares of Common Stock at $43.7864 per share to cover tax withholding on vesting Restricted Stock Units. After this sell-to-cover transaction, Cho directly holds 137,903 Twist Bioscience shares.
Twist Bioscience Corp senior vice president of human resources Paula Green reported a small sale of common stock tied to taxes on vested Restricted Stock Units. She sold 297 shares at an average price of $43.7864 per share through a mandated “sell to cover” transaction under the company’s equity incentive plans. After this tax-related sale, she directly holds 124,104 shares of Twist Bioscience common stock. The footnote explains that the transaction was required to satisfy tax withholding obligations and did not reflect a discretionary trading decision by the executive.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a small mandated share sale tied to tax withholding. On 2026-03-20, she sold 1,742 shares of common stock at an average price of $43.7864 per share to cover taxes due on vesting restricted stock units, as required under the company’s equity incentive plans and not as a discretionary trade. Following this transaction, she continued to hold 858,887 shares of common stock directly and also held employee stock options, including an award exercisable for 64,950 shares at an exercise price of $67.8500 expiring on 2030-08-31.
Twist Bioscience director Robert Chess exercised stock options for 10,000 shares of Common Stock at $11.89 per share and on the same day sold 10,000 shares at $47.00 per share in an open-market transaction. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. After the sale, he holds 21,084 shares directly and 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.
Twist Bioscience Corp’s Chief Accounting Officer, Robert F. Werner, reported a small mandated share sale linked to equity compensation. On this Form 4, he disposed of 246 shares of common stock at $46.426 per share on March 6, 2026, and held 54,799 shares afterward.
According to the footnote, the sale was required to cover tax withholding obligations from vesting Restricted Stock Units under the company’s equity plans. The transaction was executed as a “sell to cover” event and is characterized as non-discretionary rather than an elective open-market trade.
Twist Bioscience Corp officer Dennis Cho reported a small sale of 425 shares of common stock on March 6, 2026 at $46.426 per share. After the transaction, he directly held 138,257 shares. According to the footnote, the shares were sold solely to cover tax withholding on vested restricted stock units and were mandated under the company’s equity incentive plan, so they do not represent a discretionary trade.
Twist Bioscience Corp senior vice president of human resources Paula Green reported an automatic sale of company stock to cover taxes from vesting equity. On March 6, 2026, she sold 935 shares of common stock at $46.426 per share under a mandatory “sell to cover” arrangement. After this tax-related sale, she directly holds 124,401 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported selling 2,423 shares of common stock on 2026-03-06 at an average price of $46.426 per share. After this transaction, she directly holds 860,629 shares.
According to the disclosure, these shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units, under a mandated "sell to cover" arrangement, rather than as discretionary trades. She also continues to hold employee stock options, including an award exercisable for 64,950 shares of common stock at an exercise price of $67.8500 per share expiring on 2030-08-31.
Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 4,294 shares of common stock at an average price of $46.7098 per share. The transaction was a mandated “sell to cover” to satisfy tax withholding tied to vesting restricted stock units, not a discretionary trade. After this sale, Finn directly owns 284,129 Twist Bioscience shares, which includes shares acquired through the company’s employee stock purchase plan.
Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported an open-market sale of 1,693 shares of common stock. The transaction occurred on February 23, 2026 at an average price of $46.7098 per share.
According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans, and the sale was not a discretionary trade by the officer. After this sale, Werner directly holds 55,045 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,085 shares of common stock of Twist Bioscience. The shares were sold at a weighted average price of $46.7098 per share to cover tax withholding obligations tied to vesting Restricted Stock Units, under a mandated “sell to cover” arrangement rather than at his discretion.
After this tax-related transaction, Laponis beneficially owns 128,291 shares of common stock, which include shares acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an automatic sale of 7,205 shares of common stock on February 23, 2026 at an average price of $46.7098 per share. The footnotes state this sale was required to cover tax withholding obligations related to vesting restricted stock units under the company’s equity plans and did not represent a discretionary trade. Following this transaction, she directly owned 863,052 common shares. The filing also lists several employee stock option grants and their vesting terms, which remain outstanding holdings rather than new transactions.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported an open-market sale of 1,465 shares of common stock at an average price of $46.7098 per share on February 23, 2026. According to the filing, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under the company’s equity incentive plans, and the sale was mandated as a “sell to cover” transaction rather than a discretionary trade. After this tax-related sale, she beneficially owns 125,336 shares, which include shares acquired through the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 844 shares of common stock at $46.7098 per share. According to the filing, the shares were sold to cover tax withholding owed on vesting restricted stock units under a mandatory “sell to cover” arrangement, rather than a discretionary trade. After this transaction, Cho directly held 138,682 shares.
Twist Bioscience Corp senior vice president of human resources Paula Green reported an open-market sale of common stock. On February 17, 2026, she sold 39,404 shares at a weighted average price of $52.40 per share, and held 126,041 shares afterward.
Twist Bioscience Corp President and COO Patrick John Finn reported multiple transactions in the company’s stock. On February 17, 2026, he exercised two stock options covering 32,300 and 18,205 shares of common stock.
On the same date, he sold a total of 68,967 shares of common stock in open-market transactions at weighted average prices of $50.321, $51.423, $52.686 and $53.110 per share under a pre-established Rule 10b5-1 trading plan adopted on May 13, 2025. After these transactions, he directly owned 287,788 shares of Twist Bioscience common stock.
Twist Bioscience director Robert Chess reported a small tax-related share sale. On February 13, 2026, 2,184 shares of Twist Bioscience common stock were sold at $48.261 per share to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a prior election rather than a discretionary trade. Following this transaction, Chess directly held 21,084 common shares. He also indirectly held 42,528 common shares through the Chess 1997 Trust, where he and his spouse serve as the sole trustees and beneficiaries.
Twist Bioscience Corp’s President and COO Patrick John Finn reported option exercises and share sales in a pre-planned trading program. On February 12 and 13, 2026, he exercised multiple stock options for common stock at exercise prices of $23.33 and $26.66 per share, converting them into ordinary shares. Over the same two days, he sold 3,500 and 1,750 shares of common stock in open-market transactions at weighted average prices of about $50.225 and $50.041 per share, with individual sale prices ranging from $50.00 to $50.51. All transactions were executed under a Rule 10b5-1 trading plan adopted on May 13, 2025, and he held 306,250 common shares directly after the reported trades, along with remaining vested stock options.
Twist Bioscience chief financial officer Adam Laponis sold 7,000 shares of common stock in an open-market transaction at $50 per share on February 12, 2026. After this planned sale under a previously adopted Rule 10b5-1 trading plan, he directly holds 130,031 shares.
Twist Bioscience Corp executive Dennis Cho reported an open-market sale of company stock. On February 11, 2026, he sold 5,000 shares of common stock at a price of $49.93 per share. After this transaction, he directly owned 138,581 shares.
The filing notes that this sale was carried out under a Rule 10b5-1 trading plan that Cho had previously adopted on May 7, 2025. He serves as Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience, indicating the transaction involves a senior member of management.
Twist Bioscience Corp chief accounting officer Robert F. Werner reported a charitable stock gift. On 02/09/2026, he disposed of 2,000 shares of Twist Bioscience common stock in a bona fide gift to a charitable organization at a reported price of $0 per share.
Following this gift transfer, Werner directly beneficially owned 56,738 shares of Twist Bioscience common stock.
Twist Bioscience director Keith Crandell received an annual equity award of 5,095 shares of common stock on February 5, 2026 at a price of $0 per share. After this grant, he directly owns 27,571 shares of Twist Bioscience common stock.
These annual award shares will fully vest on the earlier of the one-year anniversary of the grant date or the first annual shareholder meeting after the grant, as long as he continues serving as a non‑employee director. In addition, 76,047 shares are held indirectly through the Keith L. Crandell Trust, for which he and his spouse are co‑trustees and he is the sole beneficiary.
Twist Bioscience director Melissa A. Starovasnik received an annual equity award of 5,095 shares of common stock on February 5, 2026. The shares were granted at a price of $0, increasing her directly held position to 26,722 shares after the transaction.
According to the award terms, 100% of these shares will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as she continues to serve as a non-employee director on the applicable vesting date.
Twist Bioscience director Robert P. Ragusa received an annual stock award of 5,095 common shares on February 5, 2026. The shares were granted at a price of $0 per share, reflecting a typical equity compensation grant for a non-employee director.
According to the vesting terms, 100% of this annual equity award will vest on the earlier of one year from the grant date or the first annual stockholder meeting after the grant, as long as he continues serving as a director. Following this grant, Ragusa beneficially owns 28,983 Twist Bioscience common shares in total, held directly.
Twist Bioscience director Robert Chess reported a stock grant and updated his holdings. On February 5, 2026, he received an annual equity award of 5,095 shares of common stock at a price of $0 per share, increasing his directly held shares to 23,268.
The award vests in full on the earlier of one year from grant or the first stockholder meeting after the grant, so long as he continues as a service provider. He also beneficially owns 42,528 shares indirectly through the Chess 1997 Trust, where he and his spouse are the sole trustees and beneficiaries.